Breaking news

23andMe Files For Chapter 11: Anne Wojcicki Resigns Amid Struggles to Revive Company

by THEFUTURE.TEAM

March 26, 2025

In a bold and unexpected move, 23andMe has filed for Chapter 11 bankruptcy, signaling the company’s struggle to stay afloat amid mounting financial pressure. In its filing with the Eastern District of Missouri federal bankruptcy court, the DNA testing giant revealed it has initiated the process of selling its assets in an attempt to salvage what’s left of its business. Despite the looming uncertainty, 23andMe reassured customers that it would continue operations throughout the asset sale process, emphasizing that there would be no disruptions to how customer data is stored, managed, or protected.

If the bankruptcy court approves its Chapter 11 plan, 23andMe will embark on a 45-day window to solicit bids. If multiple buyers emerge, the company will hold an auction to maximize its value. A key condition for any potential buyer: they must adhere to legal requirements for handling customer data, a significant concern after recent breaches.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

In a related shakeup, co-founder Anne Wojcicki, who once helmed the company, has stepped down as CEO. However, Wojcicki isn’t entirely distancing herself from the company—she will remain on 23andMe’s board and is reportedly preparing to bid on the company’s assets herself. Her resignation follows a failed attempt to take 23andMe private. Last month, she made a bid to acquire the company for $2.53 per share, but the deal collapsed when her partner, New Mountain Capital, pulled out. This was followed by a new bid this month, offering just 41 cents per share—a move swiftly rejected by the company’s board. In a statement on X (formerly Twitter), Wojcicki expressed her disappointment, but also her intent to pursue the company’s assets independently, citing her resignation as a strategic move to position herself better for the bidding process.

The Rise And Fall Of 23andMe

Once a market darling, 23andMe went public in 2021 through a merger with a Special Purpose Acquisition Company (SPAC), reaching a market cap of $6 billion. Wojcicki, a co-founder of the company, saw her fortune soar into the billions. But since then, the company’s stock has plummeted by over 99%, as it failed to reach profitability despite its promising start.

Adding fuel to the fire, the company suffered a major data breach in 2023, when hackers exploited recycled passwords to access sensitive user data. The breach involved over a million genetic data points, including information from high-profile individuals, and was shared across hacker forums. The exposed data included genetic ancestry, birth years, and even personal details of well-known tech figures such as Mark Zuckerberg and Elon Musk. In the aftermath, 23andMe settled in court, agreeing to pay $30 million and offer three years of security monitoring to those affected by the breach.

As 23andMe enters its next phase under bankruptcy proceedings, the company faces a steep uphill battle to regain trust and value. The fate of its assets—and its brand—now rests in the hands of potential buyers.

The Future Forbes Realty Global Properties

Citigroup Raises Eurobank Target Price Following Strong Q1 Results

Revised Target Price Reflects Strengthened Outlook

Citigroup raised its target price for Eurobank to €5.00 from €4.70 while maintaining a buy recommendation following the bank’s first-quarter results and upgraded medium-term profitability outlook. Based on Eurobank’s reference share price of €3.72 on May 15, 2026, Citigroup’s revised target implies upside potential of 34.4%, rising to 38.5% when the estimated dividend yield of 4.1% is included.

Enhanced Earnings And Comprehensive Forecasts

The upgraded analysis from Citigroup, as reported by Newmoney, points to bolstered momentum in net interest income and fee generation. The investment bank has revised its normalized earnings per share forecasts upward: 4% for 2026, 9% for 2027, and 14% for 2028, primarily driven by higher expected net interest income and increased commissions.

Scenario Analysis Offers Range Of Outcomes

Citigroup’s bullish scenario values Eurobank shares at €6.10, implying potential upside of 64%. Its downside scenario projects a share price of €3.55, approximately 4.6% below the May 15 reference level. The optimistic case assumes a return on tangible equity one percentage point higher, alongside a 100 basis point reduction in the cost of equity. Meanwhile, the negative scenario assumes a 1.5 percentage point lower return combined with a 200 basis point increase in the cost of equity.

Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram

Solid Q1 Results Support Growth Targets

Eurobank reported normalized net profits of €351 million during the first quarter, broadly in line with market expectations. Reported net profit reached €331 million after a €35 million expense linked to a voluntary exit programme involving around 200 employees. The programme is expected to generate annual savings of approximately €14 million. Net interest income increased 3% quarter-on-quarter, exceeding consensus forecasts by 2% and supporting expectations that the bank could surpass its €2.6 billion target for 2026.

Looking Ahead: Ambitious Growth And Profitable Outlook

Organic loan growth reached €1.1 billion during the quarter, supporting management’s target for €3.8 billion in annual organic credit expansion. Fee income also rose 20% year-on-year, outperforming forecasts by 4%. Citigroup projects Eurobank’s net profit will reach €1.45 billion in 2026, with earnings per share of €0.40 and a dividend of €0.20 per share.

By 2028, the bank forecasts net profit of €1.76 billion alongside further improvement in profitability metrics and dividend yield. The revised projections reinforce expectations that Eurobank will continue benefiting from stronger lending activity, resilient fee income and improving operational efficiency.